Incidence and risk factors for secondary malignancy in patients with neuroblastoma after treatment with 131I-metaiodobenzylguanidine

European Journal of Cancer

Volumn 66, Issue , 2016, Pages 144-152

  Huibregtse, Kelly E ^a,i   Vo, Kieuhoa T ^b   DuBois, Steven G ^c   Fetzko, Stephanie ^d   Neuhaus, John ^a   Batra, Vandana ^e   Maris, John M ^e   Weiss, Brian ^f   Marachelian, Araz ^g   Yanik, Greg A ^h   Matthay, Katherine K ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Dana Farber Boston Children's Cancer and Blood Disorders Center   (United States)

^d BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^e CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^f CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^g CHILDREN S HOSPITAL LOS ANGELES   (United States)

^h UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

ⁱ University of Michigan Medical Center ^*  (United States)

Author keywords

Cancer; Chemotherapy; I metaiodobenzylguanidine; MIBG; Neuroblastoma; Paediatrics; Second malignancy; SMN; Solid tumour; Survivorship

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 131; (3 IODOBENZYL)GUANIDINE; ANTINEOPLASTIC AGENT; RADIOPHARMACEUTICAL AGENT;

ADOLESCENT; ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER INCIDENCE; CANCER PATIENT; CANCER RISK; CHILD; DISEASE PREDISPOSITION; FEMALE; HEMATOLOGIC MALIGNANCY; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; MYELODYSPLASTIC SYNDROME; NEUROBLASTOMA; PLASMA CELL GRANULOMA; PRESCHOOL CHILD; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SCHOOL CHILD; SECOND CANCER; SOLID TUMOR; YOUNG ADULT; CHEMICALLY INDUCED; CLINICAL TRIAL; HEMATOLOGIC DISEASE; MULTICENTER STUDY; MULTIMODALITY CANCER THERAPY; ONSET AGE; RISK ASSESSMENT;

3-IODOBENZYLGUANIDINE; ADOLESCENT; ADULT; AGE OF ONSET; ANTINEOPLASTIC AGENTS; CHILD; CHILD, PRESCHOOL; COMBINED MODALITY THERAPY; FEMALE; HEMATOLOGIC NEOPLASMS; HUMANS; INFANT; MALE; MYELODYSPLASTIC SYNDROMES; NEOPLASMS, SECOND PRIMARY; NEUROBLASTOMA; RADIOPHARMACEUTICALS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; YOUNG ADULT;

EID: 84983483003     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2016.07.017     Document Type: Article

References (33)

1. [1] Park, J.R., Bagatell, R., London, W.B., Maris, J.M., Cohn, S.L., Mattay, K.M., et al. Children's Oncology Group's 2013 blueprint for research: neuroblastoma. Pediatr Blood Cancer 60:6 (2013), 985–993.
2. [2] Strother, D.R., London, W.B., Schmidt, M.L., Brodeur, G.M., Shimada, H., Thorner, P., et al. Outcome after surgery alone or with restricted use of chemotherapy for patients with low-risk neuroblastoma: results of Children's Oncology Group study P9641. J Clin Oncol 30:15 (2012), 1842–1848.
3. [3] Yu, A.L., Gilman, A.L., Ozkaynak, M.F., London, W.B., Kreissman, S.G., Chen, H.X., et al. Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N Engl J Med 363:14 (2010), 1324–1334.
4. [4] Kreissman, S.G., Seeger, R.C., Matthay, K.K., London, W.B., Sposto, R., Grupp, S.A., et al. Purged versus non-purged peripheral blood stem-cell transplantation for high-risk neuroblastoma (COG A3973): a randomised phase 3 trial. Lancet Oncol 14:10 (2013), 999–1008.
5. [5] Matthay, K.K., Shulkin, B., Ladenstein, R., Michon, J., Giammarile, F., Lewington, V., et al. Criteria for evaluation of disease extent by (123)I-metaiodobenzylguanidine scans in neuroblastoma: a report for the International Neuroblastoma Risk Group (INRG) Task Force. Br J Cancer 102:9 (2010), 1319–1326.
6. [6] Matthay, K.K., Yanik, G., Messina, J., Quach, A., Huberty, J., Cheng, S.C., et al. Phase II study on the effect of disease sites, age, and prior therapy on response to iodine-131-metaiodobenzylguanidine therapy in refractory neuroblastoma. J Clin Oncol 25:9 (2007), 1054–1060.
7. [7] DuBois, S.G., Matthay, K.K., 131I-Metaiodobenzylguanidine therapy in children with advanced neuroblastoma. Q J Nucl Med Mol Imaging 57:1 (2013), 53–65.
8. [8] Wilson, J.S., Gains, J.E., Moroz, V., Wheatley, K., Gaze, M.N., A systematic review of 131I-meta iodobenzylguanidine molecular radiotherapy for neuroblastoma. Eur J Cancer 50:4 (2014), 801–815.
9. [9] de Kraker, J., Hoefnagel, K.A., Verschuur, A.C., van Eck, B., van Santen, H.M., Caron, H.N., Iodine-131-metaiodobenzylguanidine as initial induction therapy in stage 4 neuroblastoma patients over 1 year of age. Eur J Cancer 44 (2008), 551–556.
10. [10] Dubois, S.G., Messina, J., Maris, J.M., Huberty, J., Glidden, D.V., Veatch, J., et al. Hematologic toxicity of high-dose iodine-131-metaiodobenzylguanidine therapy for advanced neuroblastoma. J Clin Oncol 22:12 (2004), 2452–2460.
11. [11] Matthay, K.K., DeSantes, K., Hasegawa, B., Huberty, J., Hattner, R.S., Ablin, A., et al. Phase I dose escalation of 131I-metaiodobenzylguanidine with autologous bone marrow support in refractory neuroblastoma. J Clin Oncol 16 (1998), 229–236.
12. [12] Garaventa, A., Gambini, C., Villavecchia, G., Di Cataldo, A., Bertolazzi, L., Pizzitola, M.R., et al. Second malignancies in children with neuroblastoma after combined treatment with 131I-metaiodobenzylguanidine. Cancer 97:5 (2003), 1332–1338.
13. [13] Weiss, B., Vora, A., Huberty, J., Hawkins, R.A., Matthay, K.K., Secondary myelodysplastic syndrome and leukemia following 131I-metaiodobenzylguanidine therapy for relapsed neuroblastoma. J Pediatr Hematol Oncol 25:7 (2003), 543–547.
14. [14] Matthay, K.K., Villablanca, J.G., Seeger, R.C., Stram, D.O., Harris, R.E., Ramsay, N.K., et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis- retinoic acid. Children's Cancer Group. N Engl J Med 341:16 (1999), 1165–1173.
15. [15] Baker, D.L., Schmidt, M.L., Cohn, S.L., Maris, J.M., London, W.B., Buxton, A., et al. Outcome after reduced chemotherapy for intermediate-risk neuroblastoma. N Engl J Med 363:14 (2010), 1313–1323.
16. [16] Berthold, F., Boos, J., Burdach, S., Erttmann, R., Henze, G., Hermann, J., et al. Myeloablative megatherapy with autologous stem-cell rescue versus oral maintenance chemotherapy as consolidation treatment in patients with high-risk neuroblastoma: a randomised controlled trial. Lancet Oncol 6 (2005), 649–658.
17. [17] Cohen, L.E., Gordon, J.H., Popovsky, E.Y., Gunawardene, S., Duffey-Lind, E., Lehmann, L.E., et al. Late effects in children treated with intensive multimodal therapy for high-risk neuroblastoma: high incidence of endocrine and growth problems. Bone Marrow Transplant 49:4 (2014), 502–508.
18. [18] Laverdiere, C., Cheung, N.K., Kushner, B.H., Kramer, K., Modak, S., LaQuaglia, M.P., et al. Long-term complications in survivors of advanced stage neuroblastoma. Pediatr Blood Cancer 45:3 (2005), 324–332.
19. [19] Matthay, K.K., Reynolds, C.P., Seeger, R.C., Shimada, H., Adkins, E.S., Haas-Kogan, D., et al. Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a Children's Oncology Group study. J Clin Oncol 27:7 (2009), 1007–1013.
20. [20] Moreno, L., Vaidya, S.J., Pinkerton, C.R., Lewis, I.J., Imeson, J., Machin, D., et al. Long-term follow-up of children with high-risk neuroblastoma: the ENSG5 trial experience. Pediatr Blood Cancer 60:7 (2013), 1135–1140.
21. [21] Rubino, C., Adjadj, E., Guerin, S., Guibout, C., Shamsaldin, A., Dondon, M.G., et al. Long-term risk of second malignant neoplasms after neuroblastoma in childhood: role of treatment. Int J Cancer 107:5 (2003), 791–796.
22. [22] Laverdiere, C., Liu, Q., Yasui, Y., Nathan, P.C., Gurney, J.G., Stovall, M., et al. Long-term outcomes in survivors of neuroblastoma: a report from the Childhood Cancer Survivor Study. J Natl Cancer Inst 101:16 (2009), 1131–1140.
23. [23] Federico, S.M., Allewelt, H.B., Spunt, S.L., Hudson, M.M., Wu, J., Billups, C.A., et al. Subsequent malignant neoplasms in pediatric patients initially diagnosed with neuroblastoma. J Pediatr Hematol Oncol 37:1 (2015), e6–e12.
24. [24] Martin, A., Schneiderman, J., Helenowski, I.B., Morgan, E., Dilley, K., Danner-Koptik, K., et al. Secondary malignant neoplasms after high-dose chemotherapy and autologous stem cell rescue for high-risk neuroblastoma. Pediatr Blood Cancer 61:8 (2014), 1350–1356.
25. [25] Sandoval, C., Pui, C., Bowman, L.C., Heaton, D., Hurwitz, C.A., Raimondi, S.C., et al. Secondary acute myeloid leukemia in children previously treated with alkylating agents, intercalating topoisomerase II inhibitors, and irradiation. J Clin Oncol 11:6 (1993), 1039–1045.
26. [26] Le Deley, M.C., Leblanc, T., Shamsaldin, A., Raquin, M.A., Lacour, B., Sommelet, D., et al. Risk of secondary leukemia after a solid tumor in childhood according to the dose of epipodophyllotoxins and anthracyclines: a case-control study by the Societe Francaise d'Oncologie Pediatrique. J Clin Oncol 21:6 (2003), 1074–1081.
27. [27] Smith, M.A., Rubinstein, L., Cazenave, L., Ungerleider, R.S., Maurer, H.M., Heyn, R., et al. Report of the Cancer Therapy Evaluation Program monitoring plan for secondary acute myeloid leukemia following treatment with epipodophyllotoxins. J Natl Cancer Inst 85:7 (1993), 554–558.
28. [28] Inskip, P.D., Robison, L.L., Stovall, M., Smith, S.A., Hammond, S., Mertens, A.C., et al. Radiation dose and breast cancer risk in the childhood cancer survivor study. J Clin Oncol 27:24 (2009), 3901–3907.
29. [29] Henderson, T.O., Rajaraman, P., Stovall, M., Constine, L.S., Olive, A., Smith, S.A., et al. Risk factors associated with secondary sarcomas in childhood cancer survivors: a report from the childhood cancer survivor study. Int J Radiat Oncol Biol Phys 84:1 (2012), 224–230.
30. [30] Fine, J., Gray, R., A proportional hazards maodel for the subdistribution of a competing risk. J Am Stat Assoc 94 (1999), 496–509.
31. [31] Applebaum, M.A., Henderson, T.O., Lee, S.M., Pinto, N., Volchenboum, S.L., Cohn, S.L., Second malignancies in patients with neuroblastoma: the effects of risk-based therapy. Pediatr Blood Cancer 62:1 (2015), 128–133.
32. [32] Flandin, I., Hartmann, O., Michon, J., Pinkerton, R., Coze, C., Stephan, J.L., et al. Impact of TBI on late effects in children treated by megatherapy for Stage IV neuroblastoma. A study of the French Society of Pediatric oncology. Int J Radiat Oncol Biol Phys 64:5 (2006), 1424–1431.
33. [33] Trieu, M., DuBois, S.G., Pon, E., Nardo, L., Hawkins, R.A., Marachelian, A., et al. Impact of whole-body radiation dose on response and toxicity in patients with neuroblastoma after therapy with (131) I-Metaiodobenzylguanidine (MIBG). Pediatr Blood Cancer 63:3 (2016), 436–442.